Elevance Health (NYSE:ELV – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84, Zacks reports. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period last year, the company earned $11.97 earnings per share. Elevance Health updated its FY 2026 guidance to 19.850- EPS.
Elevance Health Price Performance
Shares of Elevance Health stock opened at $333.50 on Wednesday. The business’s fifty day moving average price is $308.88 and its 200 day moving average price is $331.60. Elevance Health has a twelve month low of $273.71 and a twelve month high of $432.93. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $73.26 billion, a P/E ratio of 13.29, a PEG ratio of 1.77 and a beta of 0.49.
Elevance Health Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were issued a $1.72 dividend. The ex-dividend date was Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. Elevance Health’s payout ratio is 27.39%.
Hedge Funds Weigh In On Elevance Health
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the stock. Leerink Partners lifted their target price on shares of Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a report on Thursday, January 29th. UBS Group set a $400.00 target price on shares of Elevance Health in a report on Thursday, January 29th. Weiss Ratings cut shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Mizuho lowered their price target on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating for the company in a report on Wednesday, March 11th. Finally, Truist Financial cut their price objective on shares of Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Twelve research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Elevance Health has an average rating of “Hold” and a consensus target price of $383.38.
Check Out Our Latest Stock Analysis on ELV
About Elevance Health
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
See Also
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
